FDA com­mish nom­i­nee's fi­nan­cial dis­clo­sures re­veal a vast web of in­dus­try ties. Will they mat­ter?

Pres­i­dent Biden’s nom­i­nee to run the FDA was hit with some tepid crit­i­cism back in 2016 for be­ing too cozy with the bio­phar­ma in­dus­try be­cause some of the tri­als he ran had in­dus­try spon­sors and some of the fund­ing he took was from in­dus­try.

Nev­er­the­less, Rob Califf sailed through his con­fir­ma­tion then, and his suc­ces­sor Scott Got­tlieb showed that even clos­er ties to in­dus­try shouldn’t stop an ef­fec­tive leader from be­ing FDA com­mis­sion­er.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER